Pharmaceutical Technology on MSN

JPM26: MSD homes in on derisking strategy amid Keytruda patent cliff

MSD awaits 20 potential launches and 80 late-stage readouts across its pipeline, which it believes will double $35bn ...
The Chosun Ilbo on MSN

MSD Korea maintains R&D leadership with Keytruda

MSD is a company that is ‘serious about science.’ In 2024, its global research and development investment reached $17.9 ...